Economic Atlas
Companies/Edesa Biotech, Inc.
Company profile

Edesa Biotech, Inc.

NASDAQ: EDSA · Healthcare · Biotechnology
Canadian filerHQ Markham, ONCIK 0001540159Reports USD
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
47D
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.2M
Employees
17
as of 2026-08-19
Market cap
$55.0M
as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$0$02021
Net income-$7.2M-$7.2M2025
Operating income-$7.9M-$7.9M2025
Total assets$13.5M$13.5M2025
Liabilities$1.8M$1.8M2024
Equity$12.5M$12.5M2025

Revenue trend

FY2015 – FY2021 · USD
FY15
FY16
FY18
FY18
FY19
FY19
FY20
FY21

Revenue by segment

Filed disclosures · FY2018
By product
Product100%
By geography

Not disclosed.

The read

What is Edesa Biotech, Inc.’s revenue?

Edesa Biotech, Inc. booked $0 in FY2021 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare
Pliant Therapeutics, Inc.48DXBiotech Inc.47DEloxx Pharmaceuticals, Inc.29DArch Biopartners Inc.13DInstil Bio, Inc.36DTenax Therapeutics, Inc.49D
Key facts
CEOPardeep Nijhawan
SectorHealthcare
IndustryBiotechnology
HeadquartersMarkham, ON
ExchangeNASDAQ: EDSA
Employees17
IPO date2010-06-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.